Angsuman Chakraborty07 May 2007 06:54 am
Australia’s adult stem cell company, Mesoblast Limited has announced that the United States Food and Drug Administration (US FDA) has cleared the Investigational New Drug Submission (IND) of its US-based sister company,
Angioblast Systems Inc., to commence a Phase 2 clinical trial of its allogeneic, or ‘off-the-shelf’, adult stem cells for patients with heart attacks.
The Phase 2 clinical trial will be based at the Texas Heart Institute, and will follow a similar protocol to the one used by the same investigators in preclinical studies for the IND submission. These showed that implantation of the company’s proprietary allogeneic stem cells by catheter into damaged heart muscle resulted in significant improvement in heart function and reduction in congestive heart failure.
This clinical trial will be the first to test an allogeneic stem cell product injected by catheter into heart muscle damaged by a recent heart attack. The trial will use the latest generation catheters provided through Angioblast’s ongoing relationship with the Johnson
Filed under Advocacy, Heart, Stem Cell | Comment Below
Related?
Heart Attack Patient "100%" After Experimental Stem Cell Treatment April 26th, 2008 Mr Robin Marston, a 61-year-old bus driver from West Drayton in London, has taken part in a new clinical trial, a pioneering stem-cell program at The Barts and The London Heart Attack Center. In the first clinical trial of its kind, Doctors took stem cells from bone marrow in lower back of the patient.
Stem Cell Clinical Trial for Heart Attack Patients Reaches Safety MilestoneNovember 6th, 2005 Osiris Therapeutics, Inc. announced today that its multi-center, human clinical stem cell trial for the treatment of patients suffering from heart attacks has successfully passed the first safety milestone of the trial.
Want stem cell drug for heart attack patients?February 16th, 2009 Quickly place your order in Osiris Therapeutics Inc. This company has synthesized a medicine in collaboration with Genzyme Corp.
Stem Cell Product Trial to Treat Heart Attack Receives FDA Clearance May 10th, 2007 Australia's adult stem cell company, Mesoblast Limited has announced that the United States Food and Drug Administration (US FDA) has cleared the Investigational New Drug Submission (IND) of its US-based sister company, Angioblast Systems Inc., to commence a Phase 2 clinical trial of its allogeneic, or 'off-the-shelf', adult stem cells for patients with heart attacks. The Phase 2 clinical trial will be based at the Texas Heart Institute, and will follow a similar protocol to the one used by the same investigators in preclinical studies for the IND submission.
Groundbreaking Stem cell therapy Phase II trial on damage heart tissue treatmentApril 2nd, 2009 On March 30, Dr. Roger Gammon, a cardiologist with Austin Heart cardiology group treated the first patient in the world( a 58-year-old Central Texas man) enrolled in a groundbreaking Phase II study.
Own bone marrow stem cell effective for heart patientsOctober 31st, 2008 A Britain stem cell clinical trial has raised hope for those heart patients. The study finds that a heart patient could dramatically improve survival and quality of life, if the stem cell from his own heart can be delivered into his heart.
Stem Cells to Improve Functioning of Heart in Patients Suffering from Heart Failure or Heart AttackFebruary 7th, 2007 Doctors to conduct research on use of stem cells in improving functioning of heart damaged by an attack. The Heart Care Clinic, a group of Indian cardiovascular consultants, is planning to collaborate with the Cardiovascular Center in Aalst, Belgium in making stem cell therapy useful for helping patients with heart disease.
cardiosphere-derived stem cells proved better than purified stem cells in heart attack November 12th, 2008 Los Angeles based leading biotechnology company Capricor Inc. today announced results of the preclinical studies of its cardiosphere-derived stem cells.
Leave a Comment
